Abstracts tagged "inflammatory arthritis"

Abstract Number: 333 • 2014 ACR/ARHP Annual Meeting
Deletion of the Prolactin Receptor Aggravates the Course of Antigen-Induced Arthritis
Norma Adan, Maria G. Ledesma-Colunga, Ana L. Reyes-Lopez, Fernando Lopez-Barrera, Gonzalo Martinez de la Escalera and Carmen Clapp, Institute of Neurobiology, National University of Mexico (UNAM), Queretaro, Mexico
Background/Purpose: Prolactin (PRL), the hormone essential for lactation, may protect against joint damage in rheumatoid arthritis. PRL frequently increases in the circulation of patients with…
Abstract Number: 183 • 2014 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound Reveals Calcific Deposition Arthropathy in Seronegative Inflammatory Arthritis Patients
Sheila L. Arvikar¹, Janice Lin² and Minna J. Kohler³, ¹Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ²Dermatology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Allergy, and Immunology, Massachusetts General Hospital / Harvard Medical School, Boston, MA
Background/Purpose Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) have vastly improved the diagnosis of rheumatoid arthritis (RA), but the diagnosis and management of seronegative…
Abstract Number: 124 • 2014 ACR/ARHP Annual Meeting
Ultrasound Power Doppler Findings in the Wrists and Hands Joints of Anti-CCP Antibody Positive Individuals with Non-Specific Musculoskeletal Symptoms and the Development of Inflammatory Arthritis
Jackie L. Nam, Laura Hunt, Elizabeth M.A. Hensor, Philip G. Conaghan, Richard J. Wakefield and Paul Emery, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose The use of musculoskeletal ultrasound is increasing in rheumatology practice. Recently we have shown that use of power Doppler signal (PD) on ultrasound in…
Abstract Number: 1148 • 2013 ACR/ARHP Annual Meeting
Autologous Tolerogenic Dendritic Cells In Rheumatoid and Inflammatory Arthritis
Gillian Bell¹, Amy Anderson², Julie Diboll¹, Rachel Harry², Elaine McColl³, Anne Dickinson⁴, Catharien Hilkens¹ and John Isaacs⁵, ¹Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Clinical Trials Unit, Institute of Health and Society, NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Rheumatoid arthritis is a chronic autoimmune disease which results from a breakdown of immune tolerance. Current therapies include traditional DMARDs, anti-TNF, B cell depleting…
Abstract Number: 1014 • 2013 ACR/ARHP Annual Meeting
Test-Retest Reliability Of Five Global Measures Addressing At Work Limitations/Productivity Loss In Patients With Rheumatological Conditions
Sarah Leggett¹, Annelies Boonen², Diane Lacaille³, Dorcas Beaton⁴, Bruno Fautrel⁵, Ailsa Bosworth⁶, Catherine Hoffstetter⁷, Sabrina Dadoun⁵, Carlo Alberto Scirè⁸, Sofia Hagel⁹, Mihai Bojinca¹⁰, Carina Mihai¹¹, Antje Neuen¹², Pam Rogers¹³, Denise Linton¹⁴, Ingemar Petersson¹⁵ and Suzanne Verstappen¹⁶, ¹Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre,The University of Manchester, Manchester, United Kingdom, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ⁴Scientist, Institute for Work & Health, Toronto, ON, Canada, ⁵APHP, Pitié-Salpêtrière University Hospital, Paris, France, ⁶National Rheumatoid Arthritis Society, Maidenhead, United Kingdom, ⁷Patient partner, Toronto, ON, Canada, ⁸Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ⁹Department of Clinical Sciences Lund, Section for Rheumatology, Lund, Lund University and Skåne University Hospital, Lund, Sweden, ¹⁰Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ¹¹Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ¹²University Hospital Maastricht, Internal Medicine, Division of Rheumatology, Maastricht, Netherlands, ¹³Rheumatology, Arthritis Research Centre, Vancouver, BC, Canada, ¹⁴Mobility Clinical Research Unit, St. Michael's Hospital, Toronto, ON, Canada, ¹⁵Lund University, Department of Orthopedics, Clinical Sciences Lund, Lund, Sweden, ¹⁶Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom
Background/Purpose: There are a number of single item global measures available to explore at-work productivity loss (presenteeism) in patients with rheumatological conditions. However, test-retest data…
Abstract Number: 65 • 2013 ACR/ARHP Annual Meeting
The Frequency Of Bone Marrow Oedema Adjacent To The Cruciate Ligament Peri-Entheseal Vascular Channels In Inflammatory and Degenerative Arthritis
Daniel Binks^1,2, Melissa Matzelle³, Diane Bergin⁴, Richard J. Hodgson^2,5, Ai Lyn Tan^1,2, Ellen M. Gravallese⁶, Dennis McGonagle^1,2,7 and Aleksandra Radjenovic^1,2, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ³Department of Medicine, Division of Rheumatology, University of Massachusetts Medical School, Worcester, MA, ⁴Radiology, Galway University Hospitals, Galway, Ireland, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, Worcester, MA, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: We noted in mouse models of inflammatory arthritis (IA) that an early point of entry of inflammation into the marrow space occurred at sites…
Abstract Number: 2873 • 2013 ACR/ARHP Annual Meeting
The Ion Channel TRPV2 Is New Suppressor of Arthritis Severity and Joint Damage
Teresina Laragione^1,2, Max Brenner^1,2, Christine Beeton³ and Percio Gulko^1,2, ¹Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²Molecular Medicine, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY, ³Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX
Background/Purpose: Rheumatoid arthritis (RA) is a common and chronic disease associated with increased risk of developing disability. Disease remission is still rarely achieved and better…
Abstract Number: 2460 • 2013 ACR/ARHP Annual Meeting
Spondyloarthritis Epidemiology and Burden Phase 2 [SPEED 2] Study: Disease Progression In Axial Spondyloarthropathy (SpA)
Eric Ruderman¹, Vibeke Strand², Avani Joshi³, Yanjun Bao³, Keith Betts⁴, Pooja Chopra⁴, Michael B. McGuire⁵ and Sumati A Rao³, ¹Northwestern University, Chicago, IL, ²Stanford University, Palo Alto, CA, ³AbbVie Inc., North Chicago, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵Medical Data Analytics, Parsippany, NJ
Background/Purpose: Limited information is available on progression of non-radiographic axial spondyloarthropathy (nr-axSpA) to ankylosing spondylitis (AS) in patients with SpA meeting the Assessment of Spondyloarthritis…
Abstract Number: 2236 • 2013 ACR/ARHP Annual Meeting
Articular Inflammation Is Protected By Fat-1 During The Acute Phase Of Arthritis In Mice
Sang-Il Lee¹, Yun-Hong Cheon², Ji-Min Kim³ and Won Seok Lee², ¹Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, ²Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: Omega-3 polyunsaturated fatty acids (n-3 PUFA) are well known to exert anti-inflammatory effects. The Fat-1 transgenic (Fat-1 TG) mice are capable of producing n-3…
Abstract Number: 2051 • 2013 ACR/ARHP Annual Meeting
Characteristics and Comparison Of Patients With Cystic Fibrosis With and Without Arthritis
Heather O. Tory¹, Karen Herlyn², David Zurakowski³, Angela S. Pizzo⁴, Robert P. Sundel⁵ and Peter A. Merkel⁶, ¹Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA, ²Department of Rheumatology, University Hospital Schleswig-Holstein, Lübeck, Germany, ³Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ⁴Mercy Hospital, Portland, ME, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA, ⁶Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cystic Fibrosis (CF) is a common genetic mutation in Caucasian populations. Many patients have musculoskeletal complaints and 12% develop arthritis, including CF arthropathy (CFA),…
Abstract Number: 1923 • 2013 ACR/ARHP Annual Meeting
A Study To Determine Patient Satisfaction With a Nurse-Led Injection Clinic In Rheumatology
Margaret Saldanha¹, Kathleen Brown², Dawn Heap¹, Cynthia Mech³, Melissa Deamude¹, Kathy Kislinsky¹, Debbie McClory⁴, Alpesh Shah⁵ and William G. Bensen⁶, ¹Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ²Dr. William Bensen Rheumatology Clinic, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ³Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁴Dr. William G. Bensen Rheumatology Clinic, Rheumatology Health Team Hamilton, Hamilton, ON, Canada, ⁵Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada
Background/Purpose: There is a widening care gap in Canada between patients who need Rheumatology care and the capacity of the system to deliver that care…
Abstract Number: 1846 • 2013 ACR/ARHP Annual Meeting
Mitochondrial Dysfunction Induces An Inflammatory, Tissue-Degrading, and Angiogenic Response In Normal Human Synoviocytes
M. Noa Valcárcel-Ares¹, Romina R. Riveiro-Naveira¹, Jesus Loureiro¹, Carlos Vaamonde-García¹, Laura Hermida-Carballo¹, Francisco J. Blanco² and Maria J. López-Armada¹, ¹Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, ²Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain
Background/Purpose: Tissues affected with inflammatory arthritis (IA) are subjected to great levels of oxidative stress. Synoviocytes from IA patients present a higher rate of mitochondrial…
Abstract Number: 1470 • 2013 ACR/ARHP Annual Meeting
Anti-Tumour Necrosis Factor Alpha Therapy Reduces Platelet Reactivity and Is Associated With Improved Insulin Sensitivity In Patients With Inflammatory Arthritis
Paul A. MacMullan^1,2, Anne M. Madigan¹, Laura J. Durcan³, Karl Egan², Paola M. Bagaglia¹, Dermot Kenny⁴ and Geraldine M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Cardiovascular Biology Laboratory, RCSI, Dublin, Ireland, ³Rheumatology, Mater Misercordiae University Hospital, Dublin 7, Ireland, ⁴Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland
Background/Purpose: Patients with inflammatory arthritis (IA) die prematurely from cardiovascular disease (CVD). The increased CVD risk is not fully explained by traditional risk factors, but…
Abstract Number: 1373 • 2013 ACR/ARHP Annual Meeting
Connective Tissue Growth Factor Promotes Angiogenesis Through Increased Notch-1 Signaling in Rheumatoid Arthritis
Kazuhisa Nozawa¹, Maki Fujishiro², Ayako Yamaguchi¹, Mikiko Kawasaki², Kazuhisa Iwabuchi², Mitsuaki Yanagida², Keigo Ikeda³, Shinji Morimoto⁴, Yoshinari Takasaki⁵ and Iwao Sekigawa³, ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ⁴Juntendo University Urayasu Hospital, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan
Background/Purpose: Increased angiogenesis has been associated with various inflammatory disease states including rheumatoid arthritis (RA), and it has been considered as one of main factors…
Abstract Number: 1329 • 2013 ACR/ARHP Annual Meeting
Physician Global Assessment At Three Months Is Strongly Predictive Of Remission At 12 Months In Early Rheumatoid Arthritis. Results From The Canadian Early Arthritis Cohort
Tommy Choy¹, Vivian P. Bykerk², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, J. Carter Thorne⁶, Edward C. Keystone⁷ and Janet E. Pope⁸, ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁵Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: To determine predictors of 1-year remission in early rheumatoid arthritis (ERA) using baseline and 3 months data. Methods: The Canadian Early Arthritis Cohort (CATCH)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].